Australian clinical-stage biotechnology company Vaxxas has expanded its global intellectual property portfolio to 42 patents, supporting its exclusive claim to manufacture and sell its proprietary vaccination technology, the HD-MAP, in the US, Europe, Asia and Australia. …
Vaxxas expands global IP portfolio for exclusive manufacture and sale of needle-free vaccination technology
November 27, 2024 Australian Biotech
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 31 October
October 31, 2025 - - Podcast -
Aroa Biosurgery appoints Paul Shearer to Board as John Pinion retires
October 31, 2025 - - Australian Biotech -
Immuron provides update on U.S. clinical trials for Travelan and IMM-529
October 31, 2025 - - Australian Biotech -
Firebrick Pharma launches new Nasodine Throat Spray for international markets
October 31, 2025 - - Australian Biotech -
Amplia Therapeutics begins trading on U.S. OTCQB Venture Market
October 31, 2025 - - Australian Biotech -
DHL Supply Chain opens New Zealand’s most advanced life sciences and healthcare logistics facility
October 31, 2025 - - Latest News -
The continued 'false framing' aims to make us feel guilty for wanting more on health
October 31, 2025 - - Latest News